Bedrijfsoverzicht
Seres Therapeutics, Inc. is a clinical-stage biotechnology entity dedicated to developing biotherapeutics intended for the treatment of serious diseases, with a specific focus on SER-155, an investigational oral live biotherapeutic designed to decolonize gastrointestinal pathogens, enhance the integrity of the GI epithelial barrier, and regulate immune responses. The company operates within the Healthcare sector, specifically the Biotechnology industry, which implies a high-risk, high-reward environment where value is derived from successful clinical trials and regulatory approvals rather than current product sales. As of the latest data, Seres Therapeutics holds a market capitalization of $79.76M and employs a workforce of 66 individuals, while generating TTM revenue of $789,000. These financial metrics indicate that the company is in an early-stage development phase where revenue generation is minimal compared to its valuation, suggesting that the market price primarily reflects potential future asset value and intellectual property rights rather than established cash flow or profitability.
Financiële gezondheid
The financial statements for Seres Therapeutics, Inc. show TTM revenue of $789,000, net income of $5.70M, and an EBITDA of $-89,838,000, revealing a significant divergence between top-line activity and bottom-line profitability. The gap between the nominal revenue and the substantial net income indicates an unusual accounting dynamic where non-operating income, likely from equity stakes or other investments, drives reported profits despite negligible core operations. The company reports a free cash flow of $-54,955,876, which signifies a heavy reliance on external capital sources such as equity financing or debt issuance to fund ongoing research and development activities. Margin analysis reveals a gross margin of 0.0%, an operating margin of -4424.0%, and a profit margin of 721.9%; the zero gross margin suggests costs of goods sold are equal to revenue in the current reporting period, while the negative operating margin highlights extreme operating losses relative to revenue. The balance sheet presents a complex picture with cash reserves of $45.77M offset against total debt of $82.97M, resulting in a debt-to-equity ratio of 187.63%, which indicates a highly leveraged capital structure typical for early-stage biotechs. Despite the high debt load, the current ratio stands at 2.56, demonstrating that the company maintains sufficient liquid assets to cover short-term obligations without immediate distress. Return on Equity is reported at 19.6% while Return on Assets is -42.3%, metrics that together reveal how the company leverages its equity base to generate returns through non-operating income streams, yet assets as a whole are generating negative returns on an operating basis.
Waarderingsbeoordeling
Valuation metrics for Seres Therapeutics, Inc. present a challenging landscape for traditional analysis, with a trailing twelve-month P/E ratio of 13.00 and a forward P/E of -0.91. The stark contrast between these two figures implies that while past earnings (driven by non-operating sources) support a positive multiple, future earnings are expected to turn negative, reflecting the anticipated shift back to operating losses as the company advances its clinical pipeline. The price-to-book ratio is recorded at 1.80, indicating that the market values the company at a premium of 80% over its net asset book value, a common occurrence in biotechnology where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 101.09 and an EV/EBITDA of -1.30, which suggest that investors are pricing the stock based on potential market opportunity rather than current sales performance or earnings power. Historical price data shows a 52-week high of $29.98 and a 52-week low of $6.53, providing a range within which the current share price must be evaluated to determine if it is trading at a relative discount or premium compared to its recent volatility. The stock exhibits a beta of 0.26, which indicates that its price volatility is significantly lower than the broader market, suggesting less sensitivity to general market movements but potentially higher idiosyncratic risk associated with the specific success of its drug candidates.
Growth & Income
Regarding growth metrics, the available data lists revenue growth year-over-year and earnings growth year-over-year as N/A, preventing a direct quantitative comparison of whether earnings are growing faster or slower than revenue. In the absence of dividend distributions, the company does not offer a dividend yield or a payout ratio, as the payout ratio is recorded as 0.0%, indicating that all available earnings are retained within the company to fund operations and research rather than being distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms that must allocate capital toward advancing their drug candidates through clinical trials and regulatory review processes. Consequently, the overall growth and income profile of Seres Therapeutics, Inc. is characterized by a lack of current cash yield and undefined historical growth rates, with value derived entirely from the potential future success of its investigational biotherapeutics and the financial engineering of its balance sheet.